A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
about
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesThe latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)Combating acquired resistance to tyrosine kinase inhibitors in lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsStructure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond ProgressionMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) InhibitorsThe Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerConstruction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.Patient-reported outcomes as end points and outcome indicators in solid tumours.Emerging paradigms in targeted treatments for Asian patients with NSCLC.New strategies to develop new medications for lung cancer and metastasis.Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Safety and efficacy of targeted agents monotherapy in advanced NSCLC.Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroOsimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First LineAdvances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats.The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.Adverse kidney effects of epidermal growth factor receptor inhibitors.[TKI Resistance for T790M Mutation].
P2860
Q26778318-378789FB-CA6A-4AE3-85C6-9E1A6A0D2A26Q26797297-4BA941E7-1F36-43AD-8474-307FB10D7F99Q26823305-3D8423C9-EFE3-4431-BC3F-2FF356546981Q26824877-C73DA2A4-4B5F-4753-A5AB-A0431CCEA5DDQ27014117-2EBB2EFC-579C-480E-A85E-2A352EE0665EQ28083239-81182E44-B839-4B47-B234-2EB7EEC31287Q28086768-A5F13346-3601-4018-9045-87F1B73FC3EBQ33812445-3E99DA35-619B-44F8-A6B3-C75CFFE34F05Q33938441-6F7A685C-34F3-49B8-8768-CF3A0447E9B0Q34650994-514246F9-624C-4DE7-9920-0D562A92D86CQ35136424-124883E3-5E93-4953-BD51-8D1A2BE853A2Q36059792-664C598C-10B4-4906-AEF1-4F1ADAD3EE15Q36104980-DDD598C7-5FC3-4D05-8063-E6F4F9C8029FQ36892544-17A220B9-BA44-48B1-A4B7-BBB3D8ABA345Q37225463-B1784C42-B2E7-49CD-A3E2-0BE4982A2457Q37707704-B5AB1C98-9A19-4E62-BF00-6B2F64E46B31Q38253835-8C2B9474-AE34-4EDF-A430-DCFE60BC1FF6Q38258948-B9045CE5-74EE-4194-A221-4D01020C1109Q38292875-E28C15C4-9035-4493-86B0-8D9BEAF09741Q38371340-F3532CA0-6DAA-4C90-9286-D914357B5692Q38439446-14D0869A-7C1C-418A-A4B5-68CC45E7E6BAQ38461521-CAF90F82-AF95-4E9C-9BE0-5F5AA9335907Q38525856-81664DC8-6C38-4066-93AE-CB2FF81454CDQ38625550-F427E65E-6D44-4902-A63D-1012A744D6F3Q38630725-272F9279-EFF5-475A-A5B3-D1B2F0915A07Q38821038-91ECFDBF-F9DA-46A6-9E21-7B2B00D86E86Q38829545-63CB1502-4248-4675-A5B1-B83D1787EA7AQ38838227-BFB61C44-3F91-40F2-AEC3-5EFFC7F953BBQ38911022-83E96FA8-1D3D-48EE-BE5D-C08A84941811Q38991958-8CE2CC58-E8F3-4877-A96B-F2A63A82F9DAQ39007500-689896F9-805D-425A-8978-6EBDB8786AFCQ39114552-0FF05606-F0DE-40B1-A046-0A03606133F2Q39220897-49F9FCE2-A21E-49A3-B9C7-55C40C774CFEQ41891577-ED0E5DCB-F9F2-44A3-AC2E-968DEB363022Q42378535-4DA40573-94DC-40F8-8C43-E018C1585D09Q43195843-F35BD0E6-9774-44D9-A6BF-F7F6294B379CQ48331376-26A20FD8-779E-44F0-A6C5-B6E0A5C461D2Q53394177-3E60A6F6-F37A-49A9-9F6B-5E83BE104DCFQ53402902-30C72017-A1F3-40C7-9248-4B6A437F2C77Q54274283-3C4902B5-4FD2-49BD-84F0-CDE6D8C41D6E
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@ast
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@en
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@nl
type
label
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@ast
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@en
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@nl
prefLabel
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@ast
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@en
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@nl
P2093
P2860
P50
P356
P1433
P1476
A phase 2 trial of dacomitinib ...... or chemotherapy and erlotinib.
@en
P2093
Alicyn K Campbell
Arun Rajan
D Ross Camidge
Diana Gernhardt
Fadlo R Khuri
Ian Taylor
Jane Liang
Jeff A Engelman
Joseph P O'Connell
Marianna Koczywas
P2860
P304
P356
10.1002/CNCR.28561
P407
P577
2014-02-05T00:00:00Z